---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-041481"
form_type: "8-K"
ticker: "INAB"
cik: "0001740279"
company_name: "IN8BIO, INC."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:28:08.526504+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IN8bio reports Q2 2023 net loss of $7.7M, cash $17.0M; positive INB-200 Phase 1 data

## Summary
- Net loss $7.7M ($0.27/sh) vs $7.2M ($0.38/sh) in Q2 2022; R&D expense $4.1M, G&A $3.6M.
- Cash $17.0M as of June 30, 2023, up from $10.9M on March 31, 2023.
- INB-200 Phase 1 data: 100% of treated GBM patients (n=8) exceeded median PFS; enrollment completion expected in 2023.
- INB-400 Phase 2 trial in GBM on track to initiate enrollment in H2 2023; primary endpoint overall survival.
- R&D day scheduled for October 12, 2023 in New York City; preclinical ovarian cancer data presented at ASGCT.

## SEC filing metadata
- accession: 0000950170-23-041481
- form_type: 8-K
- ticker: INAB
- cik: 0001740279
- company_name: IN8BIO, INC.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1740279/000095017023041481/0000950170-23-041481-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1740279/000095017023041481/inab-20230810.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-041481
- JSON: https://secwatch.observer/filing/0000950170-23-041481.json
- Plain text: https://secwatch.observer/filing/0000950170-23-041481.txt

## Key facts
- Earnings Releases
  IN8BIO, INC. reported the quarter ended June 30, 2023 results: net income $7.7 million, EPS $0.27 per basic and diluted common share.
  - Period: the quarter ended June 30, 2023
  - Net income: $7.7 million
  - EPS: $0.27 per basic and diluted common share
  - Result: reported results
  source text: IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the second quarter ended June 30, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1740279/000095017023041481/0000950170-23-041481-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.